BioCentury
ARTICLE | Clinical News

Syndax pauses entinostat-PD-1/PD-L1 combo program

March 15, 2019 12:29 AM UTC

Syndax said in its 4Q18 financial results that it will "defer advancement" of its program evaluating entinostat plus PD-1/PD-L1 inhibitors after the combinations missed the primary endpoints of improving progression-free survival (PFS) in a pair of Phase Ib/II trials.

ENCORE 602 evaluated entinostat plus anti-PD-1 mAb Tecentriq atezolizumab vs. Tecentriq alone in patients with PD-1-naïve, previously treated triple-negative breast cancer (TNBC). ENCORE 603 evaluated entinostat plus anti-PD-L1 mAb Bavencio avelumab vs. Bavencio alone in patients with heavily pretreated advanced epithelial ovarian cancer...